Umoja Biopharma

David Fontana, Ph.D.,
Chief Operating Officer 

Oct. 12 | 9:30am | Rentschler ATMP Ballroom 

Seattle, WA 


Umoja Biopharma, Inc., is a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers. By reprogramming immune cells in vivo to target and fight cancer, Umoja aims to expand patient access to life-saving cell and gene therapies. Umoja’s integrated in vivo technologies and in-house manufacturing capabilities address the limitations of today’s cell/gene therapies. Umoja’s gene delivery platform, VivoVec™, delivers any chimeric antigen receptor (CAR) payload to T cells in vivo, omitting the manufacturing and logistical challenges of current CAR T-cell treatments. Additionally, Umoja’s RACR™ platform promotes the expansion and survival of generated CAR T-cells, eliminating the need for toxic lymphodepletion. Finally, Umoja’s bispecific adapters, TumorTags™, target multiple tumor elements and have the potential to unlock CAR T for solid tumors. Umoja aims to bring the promise of CAR T therapy to the masses by leveraging its technology platforms to create a robust pipeline of wholly-owned and partnered programs. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions